Which Pharma Companies Are Dx Ready For Precision Medicine in 2017? Benchmarking, Financial Risks and Predictions

Ewelina Golebiewska
Steve Vitale
Ryan Keeling

For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make considered predictions for the industry as it develops.

Listen to the webinar to learn:

  • What’s new in this year’s Pharma Readiness for Dx report
  • How the diagnostic market is currently placed and where it is heading in 2017 and beyond
  • How pharma readiness and financial risks can impact the industry

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports


TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications